Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 11/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608348 | 0.89 | COMT (0.59) | COMTALDH1A1HPGDMAPTSMN1; SMN2 | |
| SCHEMBL1608688 | 0.88 | COMT (0.58) | COMTALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL1608921 | 0.82 | COMT (0.59) | COMTALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL1608186 | 0.80 | COMT (0.73) | COMTALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1608760 | 0.76 | COMT (0.48) | COMTALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1609327 | 0.74 | COMT (0.69) | COMTALDH1A1HPGDMAPTKMT2A | |
| SCHEMBL1608934 | 0.74 | COMT (0.83) | COMTMAPTMEN1KMT2A | |
| SCHEMBL1608790 | 0.73 | COMT (0.43) | COMTALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3365763 | 0.72 | COMT (0.65) | COMTALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3454727 | 0.72 | ALDH1A1 (1.00) | ALDH1A1HPGDMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318785-B2 | Pharmaceutical compounds | ORION CORPORATION (FI) | 2012-11-27 | — | — | US | claimed |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2011-04-14 | — | — | US | claimed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | claimed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | claimed |
| EP-1910325-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2008-04-16 | — | — | EP | claimed |
| WO-2007010085-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2007-01-25 | — | — | WO | claimed |
| US-12521363-B2 | Use of levodopa, carbidopa and entacapone for treating Parkinson's disease | ORION CORPORATION (FI) | 2026-01-13 | — | — | US | disclosed |
| US-20240050394-A1 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE | ORION CORP (FI) | 2024-02-15 | — | — | US | disclosed |
| US-11771675-B2 | Use of levodopa, carbidopa and entacapone for treating Parkinson's disease | ORION CORPORATION (FI) | 2023-10-03 | — | — | US | disclosed |
| US-20210085635-A1 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE | ORION CORPORATION (FI) | 2021-03-25 | — | — | US | disclosed |
| US-10857120-B2 | Use of levodopa, carbidopa and entacapone for treating Parkinson's disease | ORION CORPORATION (FI) | 2020-12-08 | — | — | US | disclosed |
| EP-2542220-B1 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE | ORION CORP (FI) | 2016-11-02 | — | — | EP | disclosed |
| US-20150150839-A1 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE | ORION CORPORATION (FI) | 2015-06-04 | — | — | US | disclosed |
| US-20130137729-A1 | USE OF LEVODOPA, CARBIDOPA AND ENTACAPONE FOR TREATING PARKINSON'S DISEASE | ORION CORPORATION (FI) | 2013-05-30 | — | — | US | disclosed |
| US-8318785-B2 | Pharmaceutical compounds | ORION CORPORATION (FI) | 2012-11-27 | — | — | US | disclosed |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2011-04-14 | — | — | US | disclosed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | disclosed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, UGT1A1 | COMT 1/4885ALDH1A1 65/4885HPGD 163/4885 |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, CYP3A4 | COMT 1/4885ALDH1A1 233/4885HPGD 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.